Enanta Pharmaceuticals Inc (NAS:ENTA)
$ 12.465 -0.595 (-4.56%) Market Cap: 264.00 Mil Enterprise Value: 22.76 Mil PE Ratio: 0 PB Ratio: 1.59 GF Score: 70/100

Q1 2019 Enanta Pharmaceuticals Inc Earnings Call Transcript

Feb 06, 2019 / 09:30PM GMT
Release Date Price: $83.8 (+3.71%)
Operator

Good day. My name is Ian, and I will be your conference operator today.

At this time, I would like to welcome everyone to the Enanta Pharmaceuticals First Quarter Financial Results Conference Call. (Operator Instructions)

I'd now like to turn the call over to Carol Miceli. Ma'am, you may begin.

Carol Miceli
Enanta Pharmaceuticals, Inc. - Director of IR

Thank you, Ian, and thanks for joining us this afternoon. The news release with our financial results for the recent quarter was issued and is available on our website.

On the call today is Dr. Jay Luly, President and Chief Executive Officer; Paul Mellett, our Chief Financial Officer; and other members of Enanta's senior management team.

But before we begin with our formal remarks, we want to remind you that we will be making forward-looking statements, which may include our plans and expectations with respect to our product candidates and financial projections, all of which involve certain assumptions and risks beyond our control that could cause our actual developments

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot